Trial Profile
A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Eltrombopag (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms AZA-E
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Oct 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.